Neurotrack has developed a breakthrough technology that can diagnose Alzheimer’s disease (or cognitive decline, more broadly) three to six years before symptoms appear. This proprietary, clinically validated, online computer test has the potential to not only change the course of Alzheimer’s – now the third leading cause of death in the U.S. (NIH) – but represents the scalable future of diagnostic technology. Neurotrack has built their diagnostic tool based on the human preference for novelty. By using their five-minute web-based test, Neurotrack is able to identify Alzheimer’s patients years earlier than current diagnostic methods. Through Neurotrack’s NIH-backed study on cognitive behavior, they found compelling results that were instrumental to their continued product development roadmap. The company is partnering with universities, pharmaceutical companies, and Contract Research Organizations to better qualify candidates for clinical trials. Neurotrack’s digital therapy program can dramatically reduce someone’s chances of getting Alzheimer’s and is, therefore, already beginning to solve a significant problem.